<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925349</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190197</org_study_id>
    <nct_id>NCT04925349</nct_id>
  </id_info>
  <brief_title>Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy and Metachromatic Leukodystrophy</brief_title>
  <acronym>MATRIX</acronym>
  <official_title>MATRIX - &quot;Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy and Metachromatic Leukodystrophy&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a national, non-randomized, open-label, multi-site with minimal risk study in&#xD;
      adult with adrenomyeloneuropathy (AMN) and childhood subjects with cerebral ALD (cALD) or&#xD;
      late-infantile metachromatic leukodystrophy (LI-MLD) (≤17 years). 28 subjects will be&#xD;
      enrolled with one blood sample collection during one of their medical follow-up visit.&#xD;
&#xD;
      This trial will evaluate the role of innate immunity to influence disease progression in&#xD;
      X-ALD and MLD, and if the mutations related to these leukodystrophies result in a specific&#xD;
      immune response leading to the pathogenesis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      X-linked Adrenoleukodystrophy (X-ALD) and Metachromatic Leukodystrophy (MLD) are among the&#xD;
      most frequent inherited leukodystrophies in childhood and also occur in adults. Both diseases&#xD;
      are characterized by phenotypic variability and poor genotype-phenotype correlation. In&#xD;
      childhood forms of LI-MLD and childhood cerebral ALD (C-CALD) a devastating cerebral&#xD;
      demyelination and neuronal degeneration lead to a rapid neurologic degradation and premature&#xD;
      death. Patients with the adult form of X-ALD (AMN, 60% of males) display a progressive&#xD;
      spastic paraplegia without brain involvement. However, 20% of AMN patients will also develop&#xD;
      cerebral ALD.&#xD;
&#xD;
      The pathophysiology of X-ALD and MLD is still poorly understood but several arguments argue&#xD;
      for the contribution of the immune response and neuroinflammation in these leukodystrophies.&#xD;
      In X-ALD, activation of microglia (macrophages of the CNS) plays an essential role in the&#xD;
      acute demyelination phase, where a severe inflammatory process occurs. Even if MLD is not&#xD;
      considered as a neuroinflammatory disease per se, microglia activation and increased&#xD;
      inflammatory cytokines are observed in the brain of MLD patients and mice. Even if the most&#xD;
      commonly accepted hypothesis is that neuroinflammation is caused by secondary activation of&#xD;
      microglia following phagocytosis of myelin debris full of undegraded material, a primitive&#xD;
      role of macrophages (MAC) dysfunction has emerged in recent years.&#xD;
&#xD;
      MATRIX proposes to explore how disease-related mutations affect key components of MAC&#xD;
      activation responses and how it reflects on their functionality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Macrophages functionality - distribution of monocytes</measure>
    <time_frame>2 years after blood collection</time_frame>
    <description>distribution of monocytes in the CD14-/+/++ and CD16-/+ classification using flow cytometry (% of CD14++/16-; CD14++/16+; CD14+/16+; CD14-/16-)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Macrophages functionality - myelin phagocytosis capacity</measure>
    <time_frame>2 years after blood collection</time_frame>
    <description>percentage of myelin high, myelin low and myelin negative cells using flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Macrophages functionality - HLA levels</measure>
    <time_frame>2 years after blood collection</time_frame>
    <description>maximum fluorescence intensity for HLA markers using flow cytometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Macrophages metabolic profiling</measure>
    <time_frame>2 years after blood collection</time_frame>
    <description>Macrophages metabolic profiling (&gt;2000 metabolites) using liquid chromatography coupled to high resolution mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macrophages transcriptomic profiling</measure>
    <time_frame>2 years after blood collection</time_frame>
    <description>Macrophages transcriptomic profiling (&gt;1200 coding and non coding genes) : RNA sequencing using NextSeq 500 Illumina (60 million single-end, 150 base reads ) and analysis (using FastQC, Picard-Tools, Samtools and rseqc softwares</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Adrenoleukodystrophy</condition>
  <condition>Adrenomyeloneuropathy</condition>
  <condition>Metachromatic Leukodystrophy</condition>
  <arm_group>
    <arm_group_label>affected subjects</arm_group_label>
    <description>adult patients with adrenomyeloneuropathy/adrenoleukodystrophy&#xD;
children with adrenoleukodystrophy&#xD;
children with metachromatic leukodystrophy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control subjects</arm_group_label>
    <description>-healthy children</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sample collection</intervention_name>
    <description>blood sample collection</description>
    <arm_group_label>affected subjects</arm_group_label>
    <arm_group_label>control subjects</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample for MAC analyses and blood sample for blood cells count&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Childhood patients with C-ALD (3-18 years) ; Childhood patients with LI-MLD (15 months-12&#xD;
        years) ; Adults patients with AMN ; Healthy children without significant neurologic disease&#xD;
        (15 months-18 years)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Boys aged between 3 and 18 years (inclusive) diagnosed with C-CALD (elevated levels of&#xD;
             VLCFA and leukodystrophy at brain MRI)&#xD;
&#xD;
          -  Boys or girls aged between 15 months and 12 years (inclusive) diagnosed with LI-MLD&#xD;
             (onset &lt;30 months, low ARSA activity and accumulation of sulfatides in urine)&#xD;
&#xD;
          -  Adult males diagnosed with AMN (elevated VLCFA and clinical symptoms of AMN without&#xD;
             leukodystrophy at brain MRI)&#xD;
&#xD;
          -  Children (15 months-18 years) without significant neurologic disease&#xD;
&#xD;
          -  Informed consent obtained:&#xD;
&#xD;
          -  from the parents or guardian for children patients and children controls;&#xD;
&#xD;
          -  from subject himself for adult patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation to a therapeutic clinical trial&#xD;
&#xD;
          -  Treatment likely to modify the immune system&#xD;
&#xD;
          -  Unable to have a blood collection (i.e. low hemoglobin level at the investigator's&#xD;
             judgment)&#xD;
&#xD;
          -  Any other reason, to the discretion of the investigator&#xD;
&#xD;
          -  Children or adults without health insurance or social security&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Months</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fanny MOCHEL, MCU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut du Cerveau et de la Moëlle épinière</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Violetta ZUJOVIC, PhD, CR1</last_name>
    <role>Study Chair</role>
    <affiliation>Institut du Cerveau et de la Moëlle épinière</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Caroline SEVIN, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kremlin Bicêtre Hôpital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fanny MOCHEL</last_name>
    <phone>01 57 27 44 82</phone>
    <email>fanny.mochel@upmc.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christelle AUGER</last_name>
    <email>christelle.auger@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AP-HP Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fanny MOCHEL, MD-PhD</last_name>
      <phone>+33 1 5727 44 82</phone>
      <email>fanny.mochel@upmc.fr</email>
    </contact>
    <contact_backup>
      <last_name>Caroline SEVIN, MD-PhD</last_name>
      <phone>+33 1 45 21 30 17</phone>
      <email>caroline.sevin@inserm.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Fanny MOCHEL, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline SEVIN, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital La Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Miron VE, Boyd A, Zhao JW, Yuen TJ, Ruckh JM, Shadrach JL, van Wijngaarden P, Wagers AJ, Williams A, Franklin RJM, Ffrench-Constant C. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci. 2013 Sep;16(9):1211-1218. doi: 10.1038/nn.3469. Epub 2013 Jul 21.</citation>
    <PMID>23872599</PMID>
  </reference>
  <reference>
    <citation>Weinhofer I, Zierfuss B, Hametner S, Wagner M, Popitsch N, Machacek C, Bartolini B, Zlabinger G, Ohradanova-Repic A, Stockinger H, Köhler W, Höftberger R, Regelsberger G, Forss-Petter S, Lassmann H, Berger J. Impaired plasticity of macrophages in X-linked adrenoleukodystrophy. Brain. 2018 Aug 1;141(8):2329-2342. doi: 10.1093/brain/awy127.</citation>
    <PMID>29860501</PMID>
  </reference>
  <reference>
    <citation>Berger J, Forss-Petter S, Eichler FS. Pathophysiology of X-linked adrenoleukodystrophy. Biochimie. 2014 Mar;98:135-42. doi: 10.1016/j.biochi.2013.11.023. Epub 2013 Dec 4. Review.</citation>
    <PMID>24316281</PMID>
  </reference>
  <reference>
    <citation>Gieselmann V, Krägeloh-Mann I. Metachromatic leukodystrophy--an update. Neuropediatrics. 2010 Feb;41(1):1-6. doi: 10.1055/s-0030-1253412. Epub 2010 Jun 22. Review.</citation>
    <PMID>20571983</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukodystrophy</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Immune system</keyword>
  <keyword>Neuroinflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenoleukodystrophy</mesh_term>
    <mesh_term>Leukodystrophy, Metachromatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

